{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    27,
    28,
    29,
    31,
    32,
    33,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Atezolizumab",
        "type": {
          "id": "abc40b8b-a2da-4e2e-a92b-692fc4c4a4c7",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "b7bd8a89-369f-4db3-b917-7b2b02e97df1",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Humanized IgG1 monoclonal antibody that targets PD-L1",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Bevacizumab",
        "type": {
          "id": "0a8a13c7-3b15-4d8f-9296-b8be2f84dc00",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "e901bcfc-173d-439a-a691-508c94b35f82",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-VEGF therapy used in combination with atezolizumab",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Sorafenib",
        "type": {
          "id": "9837299a-4110-48ac-93fe-8b2c42691681",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "3ac7e832-766d-425a-883f-35cdad4f637d",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral multi-kinase inhibitor used as the standard of care control",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Entecavir",
        "type": {
          "id": "f8da43b5-b2f5-4364-81a8-78a1f20c230d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "e3f60fc2-bedd-45d6-9f65-f8bbfdb96913",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Example of anti-HBV treatment required for patients with active HBV"
      },
      {
        "id": "int_5",
        "name": "Herbal therapies/traditional Chinese medicines",
        "type": {
          "id": "a12973ea-7d7d-49ed-8c12-0ee8ecec998f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "31470131-fe45-4c61-9645-13114d2247eb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be discontinued prior to randomization"
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "23301e15-d3e3-48ed-be88-c0b20d8c0919",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "be1e2b13-96d5-4c0f-9dae-b70e1c6c2ad7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Systemic immunosuppressive medication; prohibited within 2 weeks prior to initiation except for specific low-dose or acute cases"
      },
      {
        "id": "int_7",
        "name": "Aspirin (>325 mg/day)",
        "type": {
          "id": "241f401c-1fdb-4f30-bd77-cbc77e78b349",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "256b4b13-9e0c-4e09-b473-eb595c71e5b5",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 10 days of first dose"
      },
      {
        "id": "int_8",
        "name": "Strong CYP3A4 inducers",
        "type": {
          "id": "cef17027-5aae-4218-b5ab-e2f43531d782",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "e693fa60-2f9b-42e8-867a-7758be696d19",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 14 days prior to initiation (e.g., rifampin, St. John's wort)"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Atezolizumab (RO5541267)",
        "administrableDoseForm": {
          "id": "481c9550-ab66-4e0c-9af8-e0ff960c7c24",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "0eba8e88-c1c1-4459-a518-9d5dda40ddb9",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "28ae3e70-4564-4fda-a595-1e95be4d12f2",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "id": "prod_2",
        "name": "Bevacizumab (RO4876646)",
        "administrableDoseForm": {
          "id": "c0f959d8-ed61-48ec-913d-f92f737818ae",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "28a2a202-13f1-419e-97f5-9be12e32d9b1",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0431dbee-a7bf-4790-bb62-ac7c6682c64b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "id": "prod_3",
        "name": "Sorafenib",
        "administrableDoseForm": {
          "id": "1f4d2bdc-553d-4b01-b041-4925ae7b2910",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "db1b324d-bb64-40b9-a326-0b91cd875f80",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0cd58dff-4818-4047-88d9-a3aa517cc0c9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_3"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Arm A: Atezolizumab",
        "instanceType": "Administration",
        "dose": "1200 mg",
        "doseFrequency": "Every 3 weeks (Q3W)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "id": "admin_2",
        "name": "Arm A: Bevacizumab",
        "instanceType": "Administration",
        "dose": "15 mg/kg",
        "doseFrequency": "Every 3 weeks (Q3W)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "id": "admin_3",
        "name": "Arm B: Sorafenib",
        "instanceType": "Administration",
        "dose": "400 mg",
        "doseFrequency": "Twice a day (BID)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Continuously until unacceptable toxicity or loss of clinical benefit"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Atezolizumab",
        "instanceType": "Substance",
        "description": "Anti-PD-L1 monoclonal antibody"
      },
      {
        "id": "sub_2",
        "name": "Bevacizumab",
        "instanceType": "Substance",
        "description": "Anti-VEGF monoclonal antibody"
      },
      {
        "id": "sub_3",
        "name": "Sorafenib",
        "instanceType": "Substance",
        "description": "Multi-kinase inhibitor"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 8,
      "productCount": 3,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Atezolizumab",
        "role": "Investigational Product",
        "description": "Humanized IgG1 monoclonal antibody that targets PD-L1"
      },
      {
        "name": "Bevacizumab",
        "role": "Investigational Product",
        "description": "Anti-VEGF therapy used in combination with atezolizumab"
      },
      {
        "name": "Sorafenib",
        "role": "Comparator",
        "description": "Oral multi-kinase inhibitor used as the standard of care control"
      },
      {
        "name": "Entecavir",
        "role": "Concomitant Medication",
        "description": "Example of anti-HBV treatment required for patients with active HBV"
      },
      {
        "name": "Herbal therapies/traditional Chinese medicines",
        "role": "Prior Medication",
        "description": "Must be discontinued prior to randomization"
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Systemic immunosuppressive medication; prohibited within 2 weeks prior to initiation except for specific low-dose or acute cases"
      },
      {
        "name": "Aspirin (>325 mg/day)",
        "role": "Concomitant Medication",
        "description": "Prohibited within 10 days of first dose"
      },
      {
        "name": "Strong CYP3A4 inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited within 14 days prior to initiation (e.g., rifampin, St. John's wort)"
      }
    ],
    "products": [
      {
        "name": "Atezolizumab (RO5541267)",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "name": "Bevacizumab (RO4876646)",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "name": "Sorafenib",
        "doseForm": "Tablet",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Atezolizumab",
        "description": "Anti-PD-L1 monoclonal antibody"
      },
      {
        "name": "Bevacizumab",
        "description": "Anti-VEGF monoclonal antibody"
      },
      {
        "name": "Sorafenib",
        "description": "Multi-kinase inhibitor"
      }
    ],
    "administrations": [
      {
        "name": "Arm A: Atezolizumab",
        "dose": "1200 mg",
        "frequency": "Every 3 weeks (Q3W)",
        "route": "Intravenous",
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "name": "Arm A: Bevacizumab",
        "dose": "15 mg/kg",
        "frequency": "Every 3 weeks (Q3W)",
        "route": "Intravenous",
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "name": "Arm B: Sorafenib",
        "dose": "400 mg",
        "frequency": "Twice a day (BID)",
        "route": "Oral",
        "duration": "Continuously until unacceptable toxicity or loss of clinical benefit"
      }
    ],
    "devices": []
  }
}